Indacaterol Versus Tiotropium on Dynamic Hyperinflation in COPD
Status:
Completed
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
Exercise intolerance is a major complain of patients with chronic obstructive pulmonary
disease (COPD). Dynamic hyperinflation has been recognized as an important limiting factor
responsible for the appearance of intolerable dyspnea during exercise. Regular treatment with
long-acting bronchodilators promotes a more sustained reduction of hyperinflation and
consequent symptom relief and increase in the patient's ability to overcome physical demands
of daily life. Tiotropium bromide (TIO) is a new generation, long-acting anticholinergic
bronchodilator that significantly improves lung function, reduces symptoms and improves
exercise tolerance in patients with advanced COPD. Indacaterol is a new ultra-long duration
(>24 h) β2-agonist, which promotes sustained dilation of the bronchi with a once-daily
administration. Compared to tiotropium, indacaterol provides evidence that is as effective as
tiotropium for bronchodilation, as well as other clinical outcomes such as dyspnea and state
of health. However, comparative effects of indacaterol versus tiotropium with regard to
outcomes in tolerance, dyspnea and dynamic lung hyperinflation during exercise is scarce. We
hypothesized that indacaterol and TIO are not different in terms of exercise tolerance and
its determinants (dynamic hyperinflation and dyspnea).
Phase:
Phase 4
Details
Lead Sponsor:
Irmandade Santa Casa de Misericórdia de Porto Alegre